An Imaging Scan (Florbetapir F-18 PET/MRI) for the Diagnosis of Peripheral Nerve Involvement in Patients with Amyloidosis

This phase I/II trial evaluates florbetapir F-18 (Amyvid) for diagnosing peripheral nerve involvement in patients with amyloidosis. Florbetapir F-18 is a radioactive medication that is given prior to a positron emission tomography/magnetic resonance imaging (PET/MRI) scan and is allowed to circulate in the body prior to the scan. The PET scanner produces three-dimensional images showing where the medication has gone in the body and the MRI allows good visualization of the soft tissues. Using florbetapir F-18 may result in a more accurate diagnosis of peripheral nerve involvement in patients with amyloidosis.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03019029.

Trial PhasePhase I/II

Trial Typediagnostic

Lead OrganizationMayo Clinic in Rochester

Principal InvestigatorStephen Broski

• Primary ID16-006798
• Secondary IDsNCI-2022-11063
• ClinicalTrials.gov IDNCT03019029